Abstract
Novel therapies for treating rheumatoid arthritis (RA) will largely be developed as a consequence of our improved understanding of immune-mediated inflammatory responses that regulate the progression of the disease process. This Special Mini “Hot-Topic” Issue of Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, entitled, Molecular Mechanisms in Rheumatic Diseases: Rationale for Novel Drug Development explores several recent developments in how new drugs will be designed for the therapy of RA by employing proteomic databases and other wellvalidated computational strategies. Furthermore, recent advances in the recognition that pro-inflammatory cytokines and the interferon family of proteins activate intracellular signal transduction pathways which control immune-mediated inflammatory responses as well as the way in which newly identified regulators of inflammation such as the Toll-like receptors contribute to RA are also discussed.
Keywords: Computational strategies, proinflammatory cytokines, interferons, proteomic databases, signal transduction pathways, Toll-like receptors, lymphocyte, anti-interleukin
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Molecular Mechanisms in Rheumatic Diseases: Rationale for Novel Drug Development – Introduction
Volume: 10 Issue: 2
Author(s): Charles J. Malemud
Affiliation:
Keywords: Computational strategies, proinflammatory cytokines, interferons, proteomic databases, signal transduction pathways, Toll-like receptors, lymphocyte, anti-interleukin
Abstract: Novel therapies for treating rheumatoid arthritis (RA) will largely be developed as a consequence of our improved understanding of immune-mediated inflammatory responses that regulate the progression of the disease process. This Special Mini “Hot-Topic” Issue of Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, entitled, Molecular Mechanisms in Rheumatic Diseases: Rationale for Novel Drug Development explores several recent developments in how new drugs will be designed for the therapy of RA by employing proteomic databases and other wellvalidated computational strategies. Furthermore, recent advances in the recognition that pro-inflammatory cytokines and the interferon family of proteins activate intracellular signal transduction pathways which control immune-mediated inflammatory responses as well as the way in which newly identified regulators of inflammation such as the Toll-like receptors contribute to RA are also discussed.
Export Options
About this article
Cite this article as:
J. Malemud Charles, Molecular Mechanisms in Rheumatic Diseases: Rationale for Novel Drug Development – Introduction, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2011; 10 (2) . https://dx.doi.org/10.2174/1871523011107020073
DOI https://dx.doi.org/10.2174/1871523011107020073 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Atherosclerotic Plaque Stabilization - Potential Role for Immunomodulatory Therapy
Vascular Disease Prevention (Discontinued) Emerging Drug Therapies and Site-Specific Interventions for Autoimmune Hepatitis
Medicinal Chemistry Reviews - Online (Discontinued) Intracellular Expression of Inflammatory Proteins S100A8 and S100A9 Leads to Epithelial-mesenchymal Transition and Attenuated Aggressivity of Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry SAR and QSAR of the Antioxidant Activity of Flavonoids
Current Medicinal Chemistry Anticancer Antifolates: Current Status and Future Directions
Current Pharmaceutical Design A Comprehensive Study of Pharmacological Behaviors, Nano-Formulations, and Applications of Rosemary
The Natural Products Journal HDL Therapy: Two Kinds of Right?
Current Pharmaceutical Design Malondialdehyde and Superoxide Dismutase in High-dose Calcium Supplemented Women in Relation to Iron and Calcium Panels
Current Nutrition & Food Science Emerging Anti-inflammatory Therapies for Atherosclerosis
Current Pharmaceutical Design Peptides Targeting Toll-Like Receptor Signalling Pathways for Novel Immune Therapeutics
Current Pharmaceutical Design The Prevention of Preterm Labour - Corticotropin Releasing Hormone Type 1 Receptors as a Target for Drug Design and Development
Mini-Reviews in Medicinal Chemistry Gender-Dependent Levels of Hyaluronic Acid in Cerebrospinal Fluid of Patients with Neurodegenerative Dementia
Current Alzheimer Research Micronutrients at the Interface Between Inflammation and Infection Ascorbic Acid and Calciferol. Part 1: General Overview with a Focus on Ascorbic Acid
Inflammation & Allergy - Drug Targets (Discontinued) Tankyrase as a Novel Molecular Target in Cancer and Fibrotic Diseases
Current Drug Targets Randomized, Placebo Controlled Study of the Effects of Etoricoxib on Markers of Inflammation, Pain and Muscle Force After Eccentric Exercise
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Prostaglandin E2 Binding Peptide: a Potential Modulatory Agent which Acts Through Suppressing NF-kappaB Signaling in RA
Protein & Peptide Letters Evaluation of the Effects of 1,25 Vitamin D3 on Regulatory T Cells and T Helper 17 Cells in Vitamin D-deficient Women with Unexplained Recurrent Pregnancy Loss
Current Molecular Pharmacology Anti Tumor Necrosis Factor-a Monoclonal Antibody (Infliximab) Therapy in Patients with Inflammatory Bowel Disease (IBD): Applications and Side Effects
Drug Design Reviews - Online (Discontinued) The Host Complement System and Arbovirus Pathogenesis
Current Drug Targets Fatty Acids - Induced Lipotoxicity and Inflammation
Current Drug Metabolism